- Home
- EVMN vs PHK Comparison
EVMN vs PHK Comparison
Compare EVMN & PHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$22.49
Company Overview
Basic Information| Metric | EVMN | PHK |
|---|---|---|
| Founded | 2020 | 2003 |
| Country | United States | United States |
| Employees | 48 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.5M | 861.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EVMN | PHK |
|---|---|---|
| Price | $22.49 | $4.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $43.88 | N/A |
| AVG Volume (30 Days) | 281.9K | ★ 604.9K |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.61% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.89 | $4.41 |
| 52 Week High | $33.20 | $5.04 |
Technical Indicators
Market Signals| Indicator | EVMN | PHK |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 38.71 |
| Support Level | $21.39 | $4.41 |
| Resistance Level | $25.50 | $4.74 |
| Average True Range (ATR) | 1.60 | 0.05 |
| MACD | -0.25 | -0.01 |
| Stochastic Oscillator | 10.55 | 20.45 |
Price Performance
Historical Comparison EVMN
PHK
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. The secondary objective of the company is to seek capital appreciation.